Aborting STEMI: What treatment opportunities may Smart-Phone ECGs give us prior to first medical contact to facilitate primary PCI?

International Journal of Cardiology

Volumn 168, Issue 6, 2013, Pages 5453-5455

  Wong, Cheuk Kit ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Anti platelet drugs; PCI; Smart Phone ECG; STEMI

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; CLOPIDOGREL; CREATINE KINASE MB; FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT; HEPARIN; PLACEBO; PRASUGREL; PURINERGIC P2Y12 RECEPTOR; TENECTEPLASE; TICAGRELOR; TIROFIBAN; TROPONIN;

CARDIOVASCULAR MORTALITY; CORONARY ARTERY THROMBOSIS; DISEASE COURSE; DRUG MEGADOSE; ELECTROCARDIOGRAPHY; FIBRINOLYTIC THERAPY; HEART EJECTION FRACTION; HEART INFARCTION SIZE; HEART MUSCLE NECROSIS; HEART MUSCLE REPERFUSION; HUMAN; INCIDENCE; LETTER; LOADING DRUG DOSE; MOBILE PHONE; PERCUTANEOUS CORONARY INTERVENTION; PLATELET REACTIVITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); ST SEGMENT ELEVATION; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; WIRELESS COMMUNICATION;

ANTI-PLATELET DRUGS; PCI; SMART PHONE ECG; STEMI;

CELLULAR PHONE; COMPUTERS, HANDHELD; ELECTROCARDIOGRAPHY; HUMANS; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS;

EID: 84887130508     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2013.04.108     Document Type: Article

References (11)

1. C.K. Wong iPhone ECG monitoring - the gateway to the new paradigm of STEMI therapy Int J Cardiol 2013 10.1016/j.ijcard.2013.03.167 [Electronic publication ahead of print]
2. W.D. Weaver, M. Cerqueira, and A.P. Hallstrom Prehospital-initiated vs hospital-initiated thrombolytic therapy JAMA 270 1993 1211 1216
3. V.C. Vasile, L. Babuin, and H.H. Ting Aborted myocardial infarction: is it real in the troponin era? Am Heart J 157 2009 636 641
4. Erratum in Am Heart J 158 2009 77
5. T. Taher, Y. Fu, and G.S. Wagner Aborted myocardial infarction in patients with ST-segment elevation: insights from the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen-3 Trial Electrocardiographic Substudy J Am Coll Cardiol 44 2004 38 43
6. T. Heestermans, A.W. van 't Hof, and J.M. ten Berg The golden hour of prehospital reperfusion with triple antiplatelet therapy: a sub-analysis from the Ongoing Tirofiban in Myocardial Evaluation 2 (On-TIME 2) trial early initiation of triple antiplatelet therapy Am Heart J 160 2010 1079 1084
7. I. Eitel, S. Desch, K. Schindler, G. Fuernau, G. Schuler, and H. Thiele Aborted myocardial infarction in intracoronary compared with standard intravenous abciximab administration in patients undergoing primary percutaneous coronary intervention for ST-elevation myocardial infarction Int J Cardiol 153 2011 21 25
8. A.K. Hassan, J.W. Jukema, and A. van der Laarse Incidence, patient characteristics and predictors of aborted myocardial infarction in patients undergoing primary PCI: prospective study comparing pre- and in-hospital abciximab pretreatment EuroIntervention 4 2009 662 668
9. A.W. van 't Hof, J. ten Berg, and T. Heestermans Ongoing Tirofiban In Myocardial infarction Evaluation (On-TIME) 2 study group. Prehospital initiation of tirofiban in patients with ST-elevation myocardial infarction undergoing primary angioplasty (On-TIME 2): a multicentre, double-blind, randomised controlled trial Lancet 372 2008 537 546
10. D. Alexopoulos, I. Xanthopoulou, and V. Gkizas Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction Circ Cardiovasc Interv 5 2012 797 804
11. C.K. Wong When should a non-STEMI be treated with primary PCI as for STEMs? Int J Cardiol 158 2012 477 478